Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Neal Flomenberg Sells 14,639 Shares

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 14,639 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $1.28, for a total transaction of $18,737.92. Following the completion of the transaction, the insider now owns 4,239,663 shares of the company’s stock, valued at approximately $5,426,768.64. The trade was a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Neal Flomenberg also recently made the following trade(s):

• On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The stock was sold at an average price of $1.10, for a total transaction of $97,370.90.

Tevogen Bio Trading Up 3.6 %

TVGN opened at $1.14 on Friday. Tevogen Bio Holdings Inc. has a 1-year low of $0.26 and a 1-year high of $7.61. The company has a 50 day simple moving average of $1.36 and a two-hundred day simple moving average of $1.16.

Hedge Funds Weigh In On Tevogen Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp boosted its position in shares of Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after acquiring an additional 13,595 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Tevogen Bio during the fourth quarter worth $55,000. Barclays PLC boosted its position in shares of Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after acquiring an additional 12,847 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after acquiring an additional 107,566 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Tevogen Bio by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after acquiring an additional 16,695 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, D. Boral Capital assumed coverage on shares of Tevogen Bio in a research report on Tuesday, March 4th. They issued a “buy” rating and a $10.00 price target for the company.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.